GSK’s linerixibat successfully meets primary study endpoint

November 19, 2024 12:34 PM GMT | By Team Kalkine Media
 GSK’s linerixibat successfully meets primary study endpoint
Image source: Shutterstock

Highlights:

  • GSK's linerixibat candidate shows positive results in Phase III trial for cholestatic pruritus in primary biliary cholangitis (PBC).

  • The trial met its primary endpoint with a statistically significant improvement in itch relief over 24 weeks compared to placebo.

  • Linerixibat could become the first global therapy to treat persistent itch in PBC patients.

GSK (LSE:GSK) has announced promising results from the GLISTEN Phase III trial of its investigational drug, linerixibat, for the treatment of cholestatic pruritus associated with primary biliary cholangitis (PBC). The trial, which involved adults suffering from the "relentless itch" linked to this rare autoimmune liver disease, demonstrated a statistically significant improvement in itch reduction over a 24-week period when compared to a placebo.

Linerixibat, which works as a targeted inhibitor of the ileal bile acid transporter, has the potential to become the first global treatment specifically designed to address the chronic and debilitating symptom of itch in PBC patients. The condition, which impacts the liver and often leads to intense and persistent itching, can severely affect a patient’s quality of life.

Kaivan Khavandi, a representative from GSK, emphasized the significance of these results, noting that the positive data highlight the potential of linerixibat to provide much-needed relief to PBC patients suffering from persistent pruritus. The company views this development as a key step forward in addressing a significant unmet need in the treatment of PBC, where few therapeutic options exist.

Despite the positive trial results, GSK shares saw a slight decline of 0.31% at 1,306.0p as of 0920 GMT on Tuesday. The results from the Phase III GLISTEN trial, however, represent a major milestone for GSK, positioning linerixibat as a potential first-line treatment for cholestatic pruritus in PBC, a critical symptom that significantly impacts patient well-being.

These findings also underscore GSK’s continued focus on advancing therapies for rare and complex conditions, reinforcing the company’s commitment to addressing unmet medical needs in areas such as liver disease.




Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


Sponsored Articles


Investing Ideas

Previous Next